Sequencing antiretrovirals

Rodger David MacArthur, J. E. Gallant

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sequencing of antiretroviral agents is of interest because the majority of HIV-infected individuals in clinical practice experience virologic rebound after 1 to 2 years of therapy. Sequencing strategies are based on the observation that different mutational patterns arise after exposure to particular antiretroviral agents within the same class and on preliminary data suggesting that not all mutations impart the same degree of cross- resistance to other agents of the same class. The ultimate goal of sequencing is to maximize the number of effective antiretroviral combinations available. While convincing data on the efficacy of sequencing strategies from large, randomized clinical trials are lacking, early data suggest that some sequencing strategies may be of benefit.

Original languageEnglish (US)
Pages (from-to)359-364
Number of pages6
JournalAIDS Reader
Volume10
Issue number6
StatePublished - Jan 1 2000

Fingerprint

Anti-Retroviral Agents
Randomized Controlled Trials
HIV
Mutation
Therapeutics

Keywords

  • Antiretroviral regimens
  • Resistance mutations
  • Sequencing strategies

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

MacArthur, R. D., & Gallant, J. E. (2000). Sequencing antiretrovirals. AIDS Reader, 10(6), 359-364.

Sequencing antiretrovirals. / MacArthur, Rodger David; Gallant, J. E.

In: AIDS Reader, Vol. 10, No. 6, 01.01.2000, p. 359-364.

Research output: Contribution to journalArticle

MacArthur, RD & Gallant, JE 2000, 'Sequencing antiretrovirals', AIDS Reader, vol. 10, no. 6, pp. 359-364.
MacArthur RD, Gallant JE. Sequencing antiretrovirals. AIDS Reader. 2000 Jan 1;10(6):359-364.
MacArthur, Rodger David ; Gallant, J. E. / Sequencing antiretrovirals. In: AIDS Reader. 2000 ; Vol. 10, No. 6. pp. 359-364.
@article{a2ed26a8c1bd4d4b93c8dda197ffdba8,
title = "Sequencing antiretrovirals",
abstract = "Sequencing of antiretroviral agents is of interest because the majority of HIV-infected individuals in clinical practice experience virologic rebound after 1 to 2 years of therapy. Sequencing strategies are based on the observation that different mutational patterns arise after exposure to particular antiretroviral agents within the same class and on preliminary data suggesting that not all mutations impart the same degree of cross- resistance to other agents of the same class. The ultimate goal of sequencing is to maximize the number of effective antiretroviral combinations available. While convincing data on the efficacy of sequencing strategies from large, randomized clinical trials are lacking, early data suggest that some sequencing strategies may be of benefit.",
keywords = "Antiretroviral regimens, Resistance mutations, Sequencing strategies",
author = "MacArthur, {Rodger David} and Gallant, {J. E.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "359--364",
journal = "AIDS Reader",
issn = "1053-0894",
publisher = "CMP Healthcare Media LLC",
number = "6",

}

TY - JOUR

T1 - Sequencing antiretrovirals

AU - MacArthur, Rodger David

AU - Gallant, J. E.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Sequencing of antiretroviral agents is of interest because the majority of HIV-infected individuals in clinical practice experience virologic rebound after 1 to 2 years of therapy. Sequencing strategies are based on the observation that different mutational patterns arise after exposure to particular antiretroviral agents within the same class and on preliminary data suggesting that not all mutations impart the same degree of cross- resistance to other agents of the same class. The ultimate goal of sequencing is to maximize the number of effective antiretroviral combinations available. While convincing data on the efficacy of sequencing strategies from large, randomized clinical trials are lacking, early data suggest that some sequencing strategies may be of benefit.

AB - Sequencing of antiretroviral agents is of interest because the majority of HIV-infected individuals in clinical practice experience virologic rebound after 1 to 2 years of therapy. Sequencing strategies are based on the observation that different mutational patterns arise after exposure to particular antiretroviral agents within the same class and on preliminary data suggesting that not all mutations impart the same degree of cross- resistance to other agents of the same class. The ultimate goal of sequencing is to maximize the number of effective antiretroviral combinations available. While convincing data on the efficacy of sequencing strategies from large, randomized clinical trials are lacking, early data suggest that some sequencing strategies may be of benefit.

KW - Antiretroviral regimens

KW - Resistance mutations

KW - Sequencing strategies

UR - http://www.scopus.com/inward/record.url?scp=0033918939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033918939&partnerID=8YFLogxK

M3 - Article

C2 - 10881367

AN - SCOPUS:0033918939

VL - 10

SP - 359

EP - 364

JO - AIDS Reader

JF - AIDS Reader

SN - 1053-0894

IS - 6

ER -